Evogene director reports stock option holdings

Evogene Ltd. director Percy Adrian John filed an initial ownership report detailing his stock option holdings in the company.

Rhea-AI Filing Summary

Evogene Ltd. director Percy Adrian John filed an initial ownership report detailing his stock option holdings in the company. The filing lists several option awards over ordinary shares with exercise prices ranging from 1.2900 to 62.6800 and expirations between 2028 and 2035.

These options cover blocks of 250 to 2,500 underlying ordinary shares each. One grant over 2,500 underlying shares at an exercise price of 1.2900 vests in four equal quarterly installments so that it is fully vested on the one-year anniversary of the August 18, 2025 grant date. The report reflects holdings only, not new market transactions.

Insider Trade Summary

8 transactions reported

Mixed 8 txns

Insider Percy Adrian John

Role Director

Type	Security	Shares	Price	Value
holding	Stock Option (right to buy ordinary shares)	--	--	--
holding	Stock Option (right to buy ordinary shares)	--	--	--
holding	Stock Option (right to buy ordinary shares)	--	--	--
holding	Stock Option (right to buy ordinary shares)	--	--	--
holding	Stock Option (right to buy ordinary shares)	--	--	--
holding	Stock Option (right to buy ordinary shares)	--	--	--
holding	Stock Option (right to buy ordinary shares)	--	--	--
holding	Stock Option (right to buy ordinary shares)	--	--	--

Holdings After Transaction: Stock Option (right to buy ordinary shares) — 11,200 contracts (Direct)

Footnotes (1)

1. F1. The options reported in this row vest equally on a quarterly basis (25% per quarter) such that they will be fully vested on the one-year anniversary of the August 18, 2025 grant date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Percy Adrian John’s Form 3 for Evogene (EVGN) report?

Percy Adrian John’s Form 3 reports his existing stock option holdings in Evogene. It lists multiple option awards over ordinary shares, specifying exercise prices, expiration dates, and underlying share amounts, providing a baseline of his derivative ownership as a company director.

Does Evogene (EVGN) director Percy Adrian John buy or sell shares in this Form 3?

The Form 3 does not show any open-market purchases or sales by Percy Adrian John. All entries are described as holdings of stock options, with no buy or sell transaction codes, highlighting only his existing derivative positions, not new trading activity.

What stock options does Percy Adrian John hold in Evogene (EVGN)?

He holds several stock options to acquire Evogene ordinary shares. The awards cover underlying blocks from 250 to 2,500 shares each, with exercise prices between 1.2900 and 62.6800 and expirations from 2028 through 2035, all reported as directly owned.

How do Percy Adrian John’s Evogene (EVGN) options vest according to the filing?

One highlighted grant of 2,500 underlying shares vests quarterly over one year. The footnote explains it vests 25% per quarter, becoming fully vested on the one-year anniversary of the August 18, 2025 grant date, aligning vesting with continued service.

What are the expiration dates on the Evogene (EVGN) options held by Percy Adrian John?

The reported stock options expire between 2028 and 2035. Individual grants show specific expiration dates such as December 23, 2028 and August 18, 2035, defining the periods during which he can exercise these rights to buy ordinary shares.

Are Percy Adrian John’s Evogene (EVGN) options held directly or through another entity?

The filing shows Percy Adrian John’s options as directly owned. Each entry is marked with direct ownership, and there is no footnote indicating that the options are held by a separate trust, partnership, or other entity on his behalf.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 08:24 AM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Percy Adrian John

(Last) (First) (Middle)

840 OVAL DRIVE

(Street)

RALEIGH NORTH CAROLINA 27606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Evogene Ltd. [ EVGN ]

3a. Foreign Trading Symbol
[EVGN]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy ordinary shares)	02/01/2023	12/23/2028	Ordinary shares	1,000	$25.6	D
Stock Option (right to buy ordinary shares)	02/01/2024	02/01/2030	Ordinary shares	250	$4.89	D
Stock Option (right to buy ordinary shares)	02/01/2025	02/01/2031	Ordinary shares	250	$62.68	D
Stock Option (right to buy ordinary shares)	08/10/2022	08/10/2031	Ordinary shares	1,800	$29.8	D
Stock Option (right to buy ordinary shares)	09/15/2023	09/15/2032	Ordinary shares	1,800	$10.2	D
Stock Option (right to buy ordinary shares)	05/11/2024	05/11/2033	Ordinary shares	1,800	$6.4	D
Stock Option (right to buy ordinary shares)	06/13/2025	06/13/2034	Ordinary shares	1,800	$6.6	D
Stock Option (right to buy ordinary shares)	(1)	08/18/2035	Ordinary shares	2,500	$1.29	D

Explanation of Responses:

1. The options reported in this row vest equally on a quarterly basis (25% per quarter) such that they will be fully vested on the one-year anniversary of the August 18, 2025 grant date.

Remarks:

Exhibit 24.1 - Power of Attorney.

	/s/ Nitsan Deutsch, attorney-in-fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)